Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NYSE: RCUS

Arcus Biosciences, Inc.

Healthcare | Biotechnology

No licensed closing price on file for RCUS. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (TTM)$-3.89

Arcus Biosciences, Inc. (NYSE: RCUS) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 09:33 UTC.

What Arcus Biosciences, Inc. does

This is a late clinical-stage biopharmaceutical company developing small-molecule drugs focused on cancer and inflammatory and autoimmune diseases. The company's most advanced programs are in Phase 3 registrational studies for cancer indications, with additional molecules in development for inflammation and autoimmune conditions. The company's lead oncology candidate, casdatifan, is an oral inhibitor being tested in multiple Phase 3 trials for clear cell renal cell carcinoma, including in combination with standard therapies and as a potential foundational treatment.

Summarized from Arcus Biosciences, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Pre-revenue, development-stage company: standard profitability ratios (P/E, EV/EBITDA, ROE) do not apply yet because there are no earnings. Watch cash, cash runway, net loss, R&D spend and share dilution instead.

Key facts

Valuation
EPS (TTM)$-3.89
Debt/equity0.22

Revenue, margins & earnings

FY2021 Net income: $53MFY2021 Operating costs: $329M$383MFY2021FY2022: net loss $267M on revenue $112M$112MFY2022FY2023: net loss $307M on revenue $117M$117MFY2023FY2024: net loss $283M on revenue $258M$258MFY2024FY2025: net loss $353M on revenue $247M$247MFY2025
  • Net income
  • Taxes & interest
  • Operating costs
  • Net loss year
Annual revenue; bands show net, operating margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-08-24
  • 2026-08-24Chief Accounting OfficerStock Option (right to buy)Option exercise-2,827—
  • 2026-08-24Chief Accounting OfficerOption exercise2,827$43.6K
  • 2026-08-24Chief Accounting OfficerSale-2,827$84.8K
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does Arcus Biosciences, Inc. do?

This is a late clinical-stage biopharmaceutical company developing small-molecule drugs focused on cancer and inflammatory and autoimmune diseases.

When did RCUS last file with the SEC?

Arcus Biosciences, Inc.'s most recent SEC filing on record is a 8-K filed 2026-06-12. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 09:33 UTC. This page is also available as JSON at /api/data?ticker=RCUS and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for RCUS and 5,000+ tickers.

Create a free account — keep RCUS
For your agent
GET /api/data?ticker=RCUS

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt